Back to EventsClinical Trial

New Trial: HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial

Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality. Studies suggest that High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a...

Body Mind StateJune 18, 20263 min read
New Trial: HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial

Trial Overview

NCT ID: NCT06719947 Phase: PHASE2, PHASE3 Enrollment Target: 80 Status: Recruiting

Amyotrophic Lateral Sclerosis (ALS) is a nervous system disease that causes muscle weakness and rapidly progresses to the loss of mobility and functionality. Studies suggest that High-Definition Transcranial Direct Current Stimulation (HD-tDCS) is a technique for modulating motor cortical hyperexcitability. However, evidence on the use of HD-tDCS as a neuromodulator of the diaphragmatic motor cortex in people with ALS is inconclusive.

Why This Matters

[Draft — editorial context needed]

Source

Event Website
ClinicalTrials.gov
Visit Event →

Related

Stay Regulated

Regulate your nervous system from the inside out.

New research, honest product reviews, neurotech funding rounds, and events — delivered weekly, with zero sponsors or ads.